President & CEO of Pediapharm (PDP:TSX.V), Sylvain Chrétien explains his company’s focus on children medicines and plans for the future.
Pediapharm is a specialty pharma with a unique approach in a sense that we’re focusing on children medicines. It is a substantial market to capture one billion plus in Canada. This market has an unmet need when it comes to children medicines and we’re there to bring new solutions for this patient population.
We have six products on the market selling. We have a pipeline of three products coming. Our main product is NYDA and this is a great innovation for head lice. The problem with head lice product in the past was the overuse of pesticide based shampoos, lice has developed resistance to those treatments. NYDA is non-pesticide treatment, meaning that, it’s impossible to develop resistance to the treatment.
Our total revenue is around $4 million mainly coming from NYDA, but we have a business plan to bring us to the $25-30 million of revenues over the next five years given the new product launches that we are going to be doing over the next few months. One in the area of allergy, this one will generate than $6 to $10 million of revenues. We have another one in the area of urine infection, this one will generate between $4 – 5 million of revenues and we have also another great innovation in the area of cerebral palpitations and this one will generate about you know $4-5 million of revenues. And this is why now we have a business plan going from four to 30 million in revenue over news over the next five-six years.